PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
19922538-10	2009	Further, the inhibitory actions of LYR-71 on IFN-gamma-induced STAT-1 phosphorylation and NO production were consistently abolished in the presence of peroxyvanadate, implying another target dependent on protein tyrosine phosphatase.	peroxyvanadate	151-165	interferon gamma	Mus musculus	45-54
19922538-10	2009	Further, the inhibitory actions of LYR-71 on IFN-gamma-induced STAT-1 phosphorylation and NO production were consistently abolished in the presence of peroxyvanadate, implying another target dependent on protein tyrosine phosphatase.	peroxyvanadate	151-165	signal transducer and activator of transcription 1	Mus musculus	63-69
10769203-3	2000	Western blotting of (&bgr;)-dystroglycan and utrophin revealed adhesion- and peroxyvanadate-dependent mobility shifts which were recognised by anti-phospho-tyrosine antibodies.	peroxyvanadate	81-95	utrophin	Homo sapiens	49-57
11956159-4	2002	Using inhibitors of serine/threonine phosphatase activity (okadaic acid) and phosphotyrosine phosphatase activity (peroxyvanadate), we can inhibit the cAMP-inducible binding of the steroidogenic factor-1 (SF-1), p54(nrb)/NonO, and polypyrimidine tract-binding protein-associated splicing factor (PSF) complex required for regulation of transcription to the promoter of hCYP17.	peroxyvanadate	115-129	splicing factor 1	Homo sapiens	181-209
11956159-4	2002	Using inhibitors of serine/threonine phosphatase activity (okadaic acid) and phosphotyrosine phosphatase activity (peroxyvanadate), we can inhibit the cAMP-inducible binding of the steroidogenic factor-1 (SF-1), p54(nrb)/NonO, and polypyrimidine tract-binding protein-associated splicing factor (PSF) complex required for regulation of transcription to the promoter of hCYP17.	peroxyvanadate	115-129	non-POU domain containing octamer binding	Homo sapiens	212-215
11956159-4	2002	Using inhibitors of serine/threonine phosphatase activity (okadaic acid) and phosphotyrosine phosphatase activity (peroxyvanadate), we can inhibit the cAMP-inducible binding of the steroidogenic factor-1 (SF-1), p54(nrb)/NonO, and polypyrimidine tract-binding protein-associated splicing factor (PSF) complex required for regulation of transcription to the promoter of hCYP17.	peroxyvanadate	115-129	non-POU domain containing octamer binding	Homo sapiens	221-225
11956159-4	2002	Using inhibitors of serine/threonine phosphatase activity (okadaic acid) and phosphotyrosine phosphatase activity (peroxyvanadate), we can inhibit the cAMP-inducible binding of the steroidogenic factor-1 (SF-1), p54(nrb)/NonO, and polypyrimidine tract-binding protein-associated splicing factor (PSF) complex required for regulation of transcription to the promoter of hCYP17.	peroxyvanadate	115-129	cytochrome P450 family 17 subfamily A member 1	Homo sapiens	369-375
11956159-5	2002	Further, both okadaic acid and peroxyvanadate attenuate cAMP-stimulated increases in endogenous hCYP17 mRNA expression and in hCYP17 promoter-reporter construct luciferase activity.	peroxyvanadate	31-45	cytochrome P450 family 17 subfamily A member 1	Homo sapiens	96-102
11956159-5	2002	Further, both okadaic acid and peroxyvanadate attenuate cAMP-stimulated increases in endogenous hCYP17 mRNA expression and in hCYP17 promoter-reporter construct luciferase activity.	peroxyvanadate	31-45	cytochrome P450 family 17 subfamily A member 1	Homo sapiens	126-132
12082117-7	2002	Tyrosine phosphatase inhibition by peroxyvanadate pretreatment reversibly mimicked the BDNF/trkB effect, indicating that tyrosine phosphorylation of Kir3 may have caused the GTPase acceleration.	peroxyvanadate	35-49	protein tyrosine phosphatase non-receptor type 9-like S homeolog	Xenopus laevis	0-20
12082117-7	2002	Tyrosine phosphatase inhibition by peroxyvanadate pretreatment reversibly mimicked the BDNF/trkB effect, indicating that tyrosine phosphorylation of Kir3 may have caused the GTPase acceleration.	peroxyvanadate	35-49	LOC108713815	Xenopus laevis	87-91
12082117-7	2002	Tyrosine phosphatase inhibition by peroxyvanadate pretreatment reversibly mimicked the BDNF/trkB effect, indicating that tyrosine phosphorylation of Kir3 may have caused the GTPase acceleration.	peroxyvanadate	35-49	neurotrophic receptor tyrosine kinase 2 L homeolog	Xenopus laevis	92-96
10769203-5	2000	In extracts from cells treated with peroxyvanadate, where endogenous (beta)-dystroglycan was tyrosine phosphorylated, (beta)-dystroglycan was no longer co-immunoprecipitated with utrophin fusion constructs.	peroxyvanadate	36-50	utrophin	Homo sapiens	179-187
28072841-4	2017	Here we report a small molecule, a peroxyvanadate compound i.e. DmpzH[VO(O2)2(dmpz)], henceforth referred as dmp, which specifically binds to insulin receptor with considerable affinity (KD-1.17muM) thus activating insulin receptor tyrosine kinase and its downstream signaling molecules resulting increased uptake of [14C] 2 Deoxy-glucose.	peroxyvanadate	35-49	dentin matrix protein 1	Mus musculus	78-81
28072841-4	2017	Here we report a small molecule, a peroxyvanadate compound i.e. DmpzH[VO(O2)2(dmpz)], henceforth referred as dmp, which specifically binds to insulin receptor with considerable affinity (KD-1.17muM) thus activating insulin receptor tyrosine kinase and its downstream signaling molecules resulting increased uptake of [14C] 2 Deoxy-glucose.	peroxyvanadate	35-49	insulin receptor	Mus musculus	142-158
28072841-4	2017	Here we report a small molecule, a peroxyvanadate compound i.e. DmpzH[VO(O2)2(dmpz)], henceforth referred as dmp, which specifically binds to insulin receptor with considerable affinity (KD-1.17muM) thus activating insulin receptor tyrosine kinase and its downstream signaling molecules resulting increased uptake of [14C] 2 Deoxy-glucose.	peroxyvanadate	35-49	insulin receptor	Mus musculus	215-231